{"nctId":"NCT00325130","briefTitle":"Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)","startDateStruct":{"date":"2006-04"},"conditions":["Neoplasms, Glandular and Epithelial","Diphtheria","Tetanus","Whooping Cough","Meningitis"],"count":1042,"armGroups":[{"label":"Group 1","type":"EXPERIMENTAL","interventionNames":["Biological: Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine","Biological: Comparator: Menactra™ (Concomitant)","Biological: Comparator: Adacel™ (Concomitant)"]},{"label":"Group 2","type":"EXPERIMENTAL","interventionNames":["Biological: Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine","Biological: Comparator: Menactra™ (Non-concomitant)","Biological: Comparator: Adacel™"]}],"interventions":[{"name":"Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine","otherNames":["Gardasil"]},{"name":"Comparator: Menactra™ (Concomitant)","otherNames":[]},{"name":"Comparator: Adacel™ (Concomitant)","otherNames":[]},{"name":"Comparator: Menactra™ (Non-concomitant)","otherNames":[]},{"name":"Comparator: Adacel™","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Must be healthy boys or girls, 11-17 years of age\n* Must be a virgin with no intention of becoming sexually active during the study period\n* Must have been properly vaccinated against diphtheria, tetanus and pertussis\n\nExclusion Criteria:\n\n* Must not have received a vaccine against diphtheria, tetanus and pertussis in the past 5 years\n* Must not have received any prior human papillomavirus (HPV) vaccine or meningococcal vaccine","healthyVolunteers":true,"sex":"ALL","minimumAge":"11 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects Who Seroconverted for Human Papillomavirus (HPV) Type 6 (HPV 6 ≥ 20 mMU/mL) by Week 4 Postdose 3 (7 Months)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"416","spread":null},{"groupId":"OG001","value":"417","spread":null}]}]}]},{"type":"SECONDARY","title":"Acceptable Safety Profile","description":null,"classes":[]},{"type":"PRIMARY","title":"Number of Subjects Who Seroconverted for HPV Type 11 (HPV 11 ≥ 16 mMU/mL) by Week 4 Postdose 3 (7 Months)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"418","spread":null},{"groupId":"OG001","value":"418","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Who Seroconverted for HPV Type 16 (HPV 16 ≥ 20 mMU/mL) by Week 4 Postdose 3 (7 Months)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"421","spread":null},{"groupId":"OG001","value":"420","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Who Seroconverted for HPV Type 18 (HPV 18≥ 24 mMU/mL) by Week 4 Postdose 3 (7 Months)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"421","spread":null},{"groupId":"OG001","value":"420","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Who Achieved a Four-fold Rise in Titers to Meningococcal Serogroup A One Month Postvaccination (Week 4 Postdose 1) With Menactra™","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"367","spread":null},{"groupId":"OG001","value":"345","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Who Achieved a Four-fold Rise in Titers to Meningococcal Serogroup C One Month Postvaccination (Week 4 Postdose 1) With Menactra™","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"423","spread":null},{"groupId":"OG001","value":"394","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Who Achieved a Four-fold Rise in Titers to Meningococcal Serogroup W-135 One Month Postvaccination (Week 4 Postdose 1) With Menactra™","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"429","spread":null},{"groupId":"OG001","value":"394","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Who Achieved a Four-fold Rise in Titers to Meningococcal Serogroup Y One Month Postvaccination With Menactra™","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"414","spread":null},{"groupId":"OG001","value":"404","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Who Achieved Acceptable Levels of Titers (Diphtheria ≥ 0.1 IU/mL) to Diphtheria One Month Postvaccination (Week 4 Postdose 1) With ADACEL™","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"397","spread":null},{"groupId":"OG001","value":"381","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Who Achieved Acceptable Levels of Titers to Tetanus (Tetanus ≥ 0.1 IU/mL) One Month Postvaccination (Week 4 Postdose 1) With ADACEL™","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"398","spread":null},{"groupId":"OG001","value":"384","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) for Anti-HPV 6 at Week 4 Postdose 3 (7 Months) of GARDASIL™","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1349.3","spread":null},{"groupId":"OG001","value":"1340.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) for Anti-HPV 11 at Week 4 Postdose 3 (7 Months) of GARDASIL™","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1609.6","spread":null},{"groupId":"OG001","value":"1513.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) for Anti-HPV 16 at Week 4 Postdose 3 (7 Months) of GARDASIL™","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7203.0","spread":null},{"groupId":"OG001","value":"7370.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) for Anti-HPV 18 at Week 4 Postdose 3 (7 Months) of GARDASIL™","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1270.2","spread":null},{"groupId":"OG001","value":"1425.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) for Pertussis Anti-Pertussis Toxin (Anti-PT) One Month Postvaccination (Week 4 Postdose 1) With ADACEL™","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.5","spread":null},{"groupId":"OG001","value":"19.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) for Pertussis Anti-Filamentous Hemagglutinin) (Anti-FHA) One Month Postvaccination (Week 4 Postdose 1) With ADACEL™","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"132.5","spread":null},{"groupId":"OG001","value":"150.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) for Pertussis Anti Pertactin (Anti-PRN) One Month Postvaccination (Week 4 Postdose 1) With ADACEL™","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"253.6","spread":null},{"groupId":"OG001","value":"274.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) for Pertussis Anti-Fimbrial Agglutinogens 2/3 (Anti-FIM) One Month Postvaccination (Week 4 Postdose 1) With ADACEL™","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"703.0","spread":null},{"groupId":"OG001","value":"611.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0},"commonTop":["Injection Site Pain ADACEL™ + Menactra™","Injection Site Pain quadrivalent HPV Vaccine postvaccination 1","Injection Site Pain qHPV Vaccine (postvaccination 3)","Injection Site Pain qHPV Vaccine (postvaccination 2)","Injection Site Swelling ADACEL™ + Menactra™"]}}}